Journal Articles Journal of Hepatology Year : 2021

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

Jörn Schattenberg
  • Function : Author
Albert Pares
  • Function : Author
Kris Kowdley
Michael Heneghan
  • Function : Author
Stephen Caldwell
  • Function : Author
Daniel Pratt
  • Function : Author
Alan Bonder
Gideon Hirschfield
  • Function : Author
Cynthia Levy
John Vierling
  • Function : Author
David Jones
  • Function : Author
Anne Tailleux
  • Function : Author
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011
Bart Staels
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011
Sophie Megnien
  • Function : Author
Remy Hanf
  • Function : Author
David Magrez
  • Function : Author
Pascal Birman
  • Function : Author
Velimir Luketic

Domains

Life Sciences [q-bio]

Anne TAILLEUX  : Connect in order to contact the contributor

https://hal.science/hal-04470428

Submitted on : Wednesday, February 21, 2024-11:05:28 AM

Last modification on : Thursday, December 19, 2024-11:12:04 AM

No file

Dates and versions

hal-04470428 , version 1 (21-02-2024)

Identifiers

Cite

Jörn Schattenberg, Albert Pares, Kris Kowdley, Michael Heneghan, Stephen Caldwell, et al.. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74 (6), pp.1344-1354. ⟨10.1016/j.jhep.2021.01.013⟩. ⟨hal-04470428⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

RIIP UNIV-LILLE RNMCD
13 View
0 Download

Altmetric

Share

More